^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    clonoSEQ

    Company:
    Adaptive Biotech
    Type:
    FDA Approved
    Evidence Level:
    Sensitive: B - Late Trials

    [TP53 mutation-Chronic Lymphocytic Leukemia-venetoclax + obinutuzumab]

    Source:
    EHA 2021
    Test:

    clonoSEQ

    Title:
    GENETIC MARKERS AND OUTCOME IN FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX - UPDATED ANALYSIS OF THE CLL14 TRIAL
    Published date:
    05/12/2021
    Excerpt:
    CONTRADICTED EVIDENCE:...gene mutations in the CLL14 trial comparing obinutuzumab+chlorambucil (GClb) vs. obinutuzumab+venetoclax (VenG) in 432 patients...Overall survival (OS) was shorter with del(17p) and TP53 mutation in both treatment arms (GClb: HR 5.7 and HR 3.1, VenG: HR 3.5 and HR 3.0, all p<0.01)...
    Trial ID:
    CLL14 study
    Evidence Level:
    Sensitive: B - Late Trials

    [Chr del(17p)-Chronic Lymphocytic Leukemia-venetoclax + obinutuzumab]

    Source:
    EHA 2021
    Test:

    clonoSEQ

    Title:
    GENETIC MARKERS AND OUTCOME IN FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX - UPDATED ANALYSIS OF THE CLL14 TRIAL
    Published date:
    05/12/2021
    Excerpt:
    CONTRADICTING EVIDENCE:…gene mutations in the CLL14 trial comparing obinutuzumab+chlorambucil (GClb) vs. obinutuzumab+venetoclax (VenG) in 432 patients (1:1) with CIRS>6 and/or creatinine clearance < 70 ml/min….Overall survival (OS) was shorter with del(17p) and TP53 mutation in both treatment arms (GClb: HR 5.7 and HR 3.1, VenG: HR 3.5 and HR 3.0, all p<0.01)…
    Trial ID:
    CLL14 study
    Evidence Level:
    Sensitive: C3 – Early Trials

    [BCR-ABL1 fusion-Acute Lymphocytic Leukemia-ponatinib + blinatumomab]

    Source:
    Blood
    Test:

    clonoSEQ

    Title:
    A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)Clinically Relevant Abstract
    Published date:
    11/15/2022
    Excerpt:
    With a median follow-up of 23 months (range, 6-31), the 2-year CRD and OS rates are 90% and 78%, respectively, across all cohorts (Figure 1), and are 89% and 82%, respectively in the ND cohort...Sequential combination of low-intensity chemotherapy and ponatinib followed by blinatumomab and ponatinib is highly effective and well tolerated in Ph+ ALL.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1182/blood-2022-167883
    Evidence Level:
    Sensitive: C3 – Early Trials

    [TP53 mutation-Chronic Lymphocytic Leukemia-venetoclax + obinutuzumab + acalabrutinib]

    Source:
    ASH 2022
    Test:

    clonoSEQ

    Title:
    344 Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
    Published date:
    11/03/2022
    Excerpt:
    In the 29 pts with TP53-aberrant disease evaluable at C16D1, the best ORR is 100% (52% CR, 48% PR)...AVO is a highly active, well-tolerated triplet in a frontline CLL population enriched for high-risk disease, with 83% of TP53-aberrant pts achieving BM-uMRD after 15 mos of tx.
    DOI:
    https://doi.org/10.1182/blood-2022-168003
    Trial ID:
    NCT03580928